MARKET

RPHM

RPHM

Reneo Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.19
-0.27
-3.19%
After Hours: 8.19 0 0.00% 16:03 07/30 EDT
OPEN
8.26
PREV CLOSE
8.46
HIGH
8.62
LOW
8.15
VOLUME
18.37K
TURNOVER
--
52 WEEK HIGH
17.18
52 WEEK LOW
7.63
MARKET CAP
198.90M
P/E (TTM)
-10.1866
1D
5D
1M
3M
1Y
5Y
BRIEF-Reneo Pharmaceuticals Says First Patient Has Been Dosed In Stride Study
reuters.com · 3d ago
Dosing underway in Reneo Pharma's mid-stage STRIDE study
Reneo Pharmaceuticals (RPHM) announces that the first patient has been dosed in Phase 2b STRIDE study.The trial is designed to evaluate the efficacy and safety of REN001 for the treatment
Seekingalpha · 3d ago
Reneo Pharmaceuticals Announces First Patient Dosed in the STRIDE Study
IRVINE, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today...
GlobeNewswire · 3d ago
We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Simply Wall St. · 07/12 13:30
Reneo Pharmaceuticals Says Retiring Officer Cleared to Sell Stock in Lock-Up Waiver
MT Newswires · 07/09 15:14
Reneo Pharmaceuticals announces partial waiver of lock-up restriction
Reneo Pharmaceuticals (RPHM) has announced that the several underwriters of Reneo’s IPO, have agreed to waive the lock-up restriction with respect to 111,736 shares of common stock held by Wendy Johnson,
Seekingalpha · 07/09 12:54
Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction
SAN DIEGO, July 09, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, announced ...
GlobeNewswire · 07/09 12:00
Reneo Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference
SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today an...
GlobeNewswire · 07/07 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RPHM. Analyze the recent business situations of Reneo Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RPHM stock price target is 31.33 with a high estimate of 45.00 and a low estimate of 24.00.
EPS
Institutional Holdings
Institutions: 2
Institutional Holdings: 751.50K
% Owned: 3.09%
Shares Outstanding: 24.29M
TypeInstitutionsShares
Increased
0
0
New
2
751.50K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.07%
Pharmaceuticals & Medical Research
-0.24%
Key Executives
Chairman/Founder/Executive Director
Mike Grey
President/Chief Executive Officer/Director
Gregory Flesher
Co-Founder/Director
Niall O'donnell
Chief Financial Officer/Primary Contact
Vinny Jindal
Vice President - Operations
Lynn Purkins
Other
Alejandro Dorenbaum
No Data
About RPHM
Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the developing therapies for patients with rare genetic mitochondrial diseases. The Company is engaged in developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the source of energy for cellular processes. REN001 is a selective peroxisome proliferator-activated receptor delta (PPARd) agonist that has been shown to transcription of genes involved in mitochondrial function and fatty acid oxidation (FAO). The Company is developing REN001 in the three rare genetic diseases that present with myopathy and have unmet medical need: primary mitochondrial myopathies (PMM), long-chain fatty acid oxidation disorders (LC-FAOD), and glycogen storage disease type V (McArdle disease). The Company has completed Phase I b clinical trial in patients with PMM to REN001. It is conducting open-label Phase I b clinical trials of REN001 with LC-FAOD and with McArdle disease.

Webull offers kinds of Reneo Pharmaceuticals Inc stock information, including NASDAQ:RPHM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RPHM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RPHM stock methods without spending real money on the virtual paper trading platform.